✦ LIBER ✦

Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer

✍ Scribed by Chloe E. Atreya, Gregory S. Ducker, Morris E. Feldman, Emily K. Bergsland, Robert S. Warren, Kevan M. Shokat

Book ID: 118299086
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 832 KB
Volume: 30
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-012-9793-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mammalian Target of Rapamycin Inhibitors

Mammalian Target of Rapamycin Inhibitors in Combination with Letrozole in Breast Cancer

✍ Philippe Chollet; Catherine Abrial; Olivier Tacca; Marie-Ange Mouret-Reynier; Ma 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 68 KB

2020 POSTER Dual Phosphoinositide 3-Kina

2020 POSTER Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor is an Effective Radiosensitizer for the Treatment of Colorectal Cancer

✍ Y.H. Chen; S.H. Kuo; M.F. Wei; S.L. Pan; C.W. Wang; H.J. Jeng; M. Gao; C.M. Teng 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Efficacy and safety of sorafenib in comb

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation

✍ Carlos Gomez-Martin; Javier Bustamante; Javier F. Castroagudin; Magdalena Salced 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 1 views

There is currently no consensus on the most suitable treatment for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation. This open, multicenter, retrospective, uncontrolled cohort study was designed to evaluate the safety and preliminary efficacy of the combined use of a mamm

Phase 1 and pharmacokinetic study of eve

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer

✍ Suresh S. Ramalingam; R. Donald Harvey; Nabil Saba; Taofeek K. Owonikoko; John K 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

AZD8055 Is a Potent, Selective, and Oral

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

✍ Chresta, C. M.; Davies, B. R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow 📂 Article 📅 2009 🏛 American Association for Cancer Research 🌐 English ⚖ 932 KB

ChemInform Abstract: Synthesis of 4-(Phe

ChemInform Abstract: Synthesis of 4-(Phenylamino)pyrimidine Derivatives as ATP-Competitive Protein Kinase Inhibitors with Potential for Cancer Chemotherapy

✍ G. W. Rewcastle; W. A. Denny; H. D. H. Showalter 📂 Article 📅 2001 🏛 John Wiley and Sons ⚖ 25 KB 👁 2 views